Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 2, 2015, Pages 295-305

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bevacizumab; Chemotherapy; Combined treatment; Neuroendocrine neoplasms

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY;

CLINICAL TRIAL (TOPIC); HUMAN; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84925286683     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1757-5     Document Type: Review

References (40)

1. Aaltonen L, Hamilton S (2000) World Health Organization. Oxford, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. IARC Press; Oxford University Press Distributor, Lyon
2. Abdel-Rahman O, Fouad M (2014) Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev Anticancer Ther [Epub ahead of print]
3. Abdel-Rahman O, Abdelwahab M, Shaker M, AbdelWahab S, Elbassiony M, Ellithy M (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol (3):655. doi:10.1007/s12032-013-0655-z. Epub 2013 Jul 4
4. Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E et al (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer 14(1):184. doi:10.1186/1471-2407-14-184
5. Bosman F (2010), World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. (4th ed.)International Agency for Research on Cancer, Lyon
6. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F (2009) Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 9:388. doi:10.1186/1471-2407-9-388
7. Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García-Carbonero R et al (2013) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish neuroendocrine tumour group (GETNE0801). Eur J Cancer 49(18):3780–3787. doi:10.1016/j.ejca.2013.06.042 Epub 2013 Sep 5
8. Chan JA, Mayer RJ, Jackson N et al (2013) Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumours. Cancer Chemother Pharmacol 71(5):1241–1246. doi:10.1007/s00280-013-2118-9 Epub 2013 Mar 9
9. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R et al (2012) Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30(24):2963–2968. doi:10.1200/JCO.2011.40.3147 Epub 2012 Jul 9
10. Firdaus I, Shih K, Zakari A, Lang E, McCleod M, Alguire K et al. (2012) Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). J Clin Oncol 30(suppl; abstr 4127)
11. Hobday T, Qin R, Reidy D, Moore M, Strosberg J, Kaubisch A et al. Multi-center Phase II Trial of Temsirolimus (TEM) and Bevacizumab (BEV) in Pancreatic Neuroendocrine Tumor (PNET): Results of a Planned interim analysis. http://www.nanets.net/nanets_cd/2012/pdfs/C19hobdayabstract.pdf. Accessed 29 April 2014
12. Hobday T, Rubin J, Holen K et al. (2007) MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 25(18_suppl):4504
13. Kasuya K, Nagakawa Y, Suzuki M, Suzuki Y, Kyo B, Suzuki S et al (2012) Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma. Exp Ther Med 3(4):599–602 Epub 2012 Jan 18
14. Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl. 1):S1–S16
15. Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A et al. (2012), Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer 19(1):L1–4. doi:10.1530/ERC-11-0287. Print 2012 Feb
16. Kuiper P, Hawinkels LJ, de Jonge-Muller ES, Biemond I, Lamers CB, Verspaget HW (2011) Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 17(2):219–225. doi:10.3748/wjg.v17.i2.219
17. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al (2006a) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406
18. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al (2006b) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406
19. Lam ET, Ringel MD, Kloos RT et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323–2330. doi:10.1200/JCO.2009.25.0068 Epub 2010 Apr 5
20. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309
21. Marton I, Knezevic F, Ramic S, Milosevic M (2012) Tomas D Immunohistochemical expression and prognostic significance of HIF-1α and VEGF-C in neuroendocrine breast cancer. Anticancer Res 32(12):5227–5232
22. Modlin I, Moss S, Chung D et al (2008a) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumours. J Natl Cancer Inst 100:1282–1289
23. Modlin I, Oberg K, Chung D et al (2008b) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72
24. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012
25. Oberg K, Jelic S (2009) Neuroendocrine gastroenteropancreatic tumours: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl. 4):150–153
26. Oberg K, Astrup L, Eriksson B et al (2004a) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 43:626–636
27. Oberg K, Astrup L, Eriksson B et al (2004b) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 43:617–625
28. Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D (2005) Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 62(4):434–443
29. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005–2012. doi:10.1016/S0140-6736(11)61742-X Epub 2011 Nov 25
30. Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K et al (2014) An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer 110(1):115–122. doi:10.1038/bjc.2013.682 Epub 2013 Nov 14
31. Plockinger U, Rindi G, Arnold R et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394–424
32. Ramage J, Davies A, Ardill J et al. (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54(Suppl. 4), pp. iv1–16
33. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513. doi:10.1056/NEJMoa1003825
34. Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663
35. Tischer E et al (1989) Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 165:1198–1206
36. Varker KA, Campbell J, Shah MH (2008) Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61(4):661–668 Epub 2007 Jun 23
37. Volante M, Righi L, Berruti A et al (2011) The pathological diagnosis of neuroendocrine tumours: common questions and tentative answers. Virchows Arch 458:393–402
38. Yao J, Phan A, Hess K, Fogelman D, Jacobs C, Dagohoy C et al. Randomized run-in study of Bevacizumab and Everolimus in low- to intermediate- grade neuroendocrine tumor (LGNETs) using perfusion CT (pCT) as functional biomarker. http://www.nanets.net/nanets_cd/2010/pdfs/C36.pdf. Accessed 29 April 2014
39. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316–1323. doi:10.1200/JCO.2007.13.6374
40. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523. doi:10.1056/NEJMoa1009290